ID   KEAP1_HUMAN             Reviewed;         624 AA.
AC   Q14145; B3KPD5; Q6LEP0; Q8WTX1; Q9BPY9;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2007, sequence version 2.
DT   18-JUN-2025, entry version 234.
DE   RecName: Full=Kelch-like ECH-associated protein 1 {ECO:0000303|PubMed:14585973};
DE   AltName: Full=Cytosolic inhibitor of Nrf2 {ECO:0000303|Ref.1};
DE            Short=INrf2 {ECO:0000303|Ref.1};
DE   AltName: Full=Kelch-like protein 19 {ECO:0000312|HGNC:HGNC:23177};
GN   Name=KEAP1 {ECO:0000303|PubMed:14585973, ECO:0000312|HGNC:HGNC:23177};
GN   Synonyms=INRF2 {ECO:0000303|Ref.1}, KIAA0132
GN   {ECO:0000303|PubMed:8590280}, KLHL19 {ECO:0000312|HGNC:HGNC:23177};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RA   Dhakshinamoorthy S., Jaiswal A.K.;
RT   "Human INrf2 gene structure and nucleotide sequence.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-349.
RC   TISSUE=Bone marrow;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV. The
RT   coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [3]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, MUTAGENESIS OF CYS-151; CYS-273 AND CYS-288, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=14585973; DOI=10.1128/mcb.23.22.8137-8151.2003;
RA   Zhang D.D., Hannink M.;
RT   "Distinct cysteine residues in Keap1 are required for Keap1-dependent
RT   ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive
RT   agents and oxidative stress.";
RL   Mol. Cell. Biol. 23:8137-8151(2003).
RN   [8]
RP   INTERACTION WITH NFE2L2 AND BPTF, FUNCTION, TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15379550; DOI=10.1021/bi0494166;
RA   Strachan G.D., Morgan K.L., Otis L.L., Caltagarone J., Gittis A.,
RA   Bowser R., Jordan-Sciutto K.L.;
RT   "Fetal Alz-50 clone 1 interacts with the human orthologue of the Kelch-like
RT   Ech-associated protein.";
RL   Biochemistry 43:12113-12122(2004).
RN   [9]
RP   FUNCTION, INTERACTION WITH CUL3 AND RBX1, MUTAGENESIS OF 125-ILE--GLY-127
RP   AND 162-TYR--ILE-164, AND UBIQUITINATION.
RX   PubMed=15572695; DOI=10.1128/mcb.24.24.10941-10953.2004;
RA   Zhang D.D., Lo S.-C., Cross J.V., Templeton D.J., Hannink M.;
RT   "Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent
RT   ubiquitin ligase complex.";
RL   Mol. Cell. Biol. 24:10941-10953(2004).
RN   [10]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH CUL3 AND RBX1, UBIQUITINATION,
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-151.
RX   PubMed=15983046; DOI=10.1074/jbc.m501279200;
RA   Zhang D.D., Lo S.C., Sun Z., Habib G.M., Lieberman M.W., Hannink M.;
RT   "Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3,
RT   targets Keap1 for degradation by a proteasome-independent pathway.";
RL   J. Biol. Chem. 280:30091-30099(2005).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE BCR(KEAP1) COMPLEX,
RP   INTERACTION WITH NFE2L2, AND MUTAGENESIS OF 123-VAL--GLY-127 AND
RP   161-MET-TYR-162.
RX   PubMed=15601839; DOI=10.1128/mcb.25.1.162-171.2005;
RA   Furukawa M., Xiong Y.;
RT   "BTB protein Keap1 targets antioxidant transcription factor Nrf2 for
RT   ubiquitination by the Cullin 3-Roc1 ligase.";
RL   Mol. Cell. Biol. 25:162-171(2005).
RN   [12]
RP   INTERACTION WITH PTMA, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-308 AND
RP   LEU-310.
RX   PubMed=15657435; DOI=10.1128/mcb.25.3.1089-1099.2005;
RA   Karapetian R.N., Evstafieva A.G., Abaeva I.S., Chichkova N.V.,
RA   Filonov G.S., Rubtsov Y.P., Sukhacheva E.A., Melnikov S.V., Schneider U.,
RA   Wanker E.E., Vartapetian A.B.;
RT   "Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications
RT   for expression of oxidative stress-protecting genes.";
RL   Mol. Cell. Biol. 25:1089-1099(2005).
RN   [13]
RP   FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151.
RX   PubMed=19489739; DOI=10.1042/bj20090471;
RA   Eggler A.L., Small E., Hannink M., Mesecar A.D.;
RT   "Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE)
RT   activation are dependent on the partial molar volume at position 151 of
RT   Keap1.";
RL   Biochem. J. 422:171-180(2009).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH NFE2L2.
RX   PubMed=16006525; DOI=10.1073/pnas.0502402102;
RA   Eggler A.L., Liu G., Pezzuto J.M., van Breemen R.B., Mesecar A.D.;
RT   "Modifying specific cysteines of the electrophile-sensing human Keap1
RT   protein is insufficient to disrupt binding to the Nrf2 domain Neh2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:10070-10075(2005).
RN   [15]
RP   INTERACTION WITH NFE2L1.
RX   PubMed=16687406; DOI=10.1074/jbc.m602802200;
RA   Wang W., Chan J.Y.;
RT   "Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal
RT   transmembrane domain. Inhibition of nuclear translocation and transacting
RT   function.";
RL   J. Biol. Chem. 281:19676-19687(2006).
RN   [16]
RP   INTERACTION WITH PGAM5, FUNCTION, ACTIVITY REGULATION, DOMAIN, AND
RP   MUTAGENESIS OF CYS-151; TYR-334; ARG-415; ARG-483 AND TYR-572.
RX   PubMed=17046835; DOI=10.1074/jbc.m606539200;
RA   Lo S.-C., Hannink M.;
RT   "PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-
RT   regulated Keap1-dependent ubiquitin ligase complex.";
RL   J. Biol. Chem. 281:37893-37903(2006).
RN   [17]
RP   FUNCTION, ACTIVITY REGULATION, AND INTERACTION WITH CUL3.
RX   PubMed=17127771; DOI=10.1074/jbc.m607622200;
RA   Gao L., Wang J., Sekhar K.R., Yin H., Yared N.F., Schneider S.N., Sasi S.,
RA   Dalton T.P., Anderson M.E., Chan J.Y., Morrow J.D., Freeman M.L.;
RT   "Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the
RT   association between Keap1 and Cullin3.";
RL   J. Biol. Chem. 282:2529-2537(2007).
RN   [18]
RP   FUNCTION, ACTIVITY REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151.
RX   PubMed=18251510; DOI=10.1021/tx700302s;
RA   Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C.,
RA   Freeman M.L.;
RT   "Covalent modification at Cys151 dissociates the electrophile sensor Keap1
RT   from the ubiquitin ligase CUL3.";
RL   Chem. Res. Toxicol. 21:705-710(2008).
RN   [19]
RP   INTERACTION WITH NFE2L2 AND PGAM5.
RX   PubMed=18387606; DOI=10.1016/j.yexcr.2008.02.014;
RA   Lo S.-C., Hannink M.;
RT   "PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to
RT   mitochondria.";
RL   Exp. Cell Res. 314:1789-1803(2008).
RN   [20]
RP   INTERACTION WITH ENC1, AND SUBCELLULAR LOCATION.
RX   PubMed=19424503; DOI=10.1371/journal.pone.0005492;
RA   Wang X.J., Zhang D.D.;
RT   "Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational
RT   level.";
RL   PLoS ONE 4:E5492-E5492(2009).
RN   [21]
RP   INTERACTION WITH SQSTM1, AND ACTIVITY REGULATION.
RX   PubMed=20495340; DOI=10.4161/auto.6.5.12189;
RA   Fan W., Tang Z., Chen D., Moughon D., Ding X., Chen S., Zhu M., Zhong Q.;
RT   "Keap1 facilitates p62-mediated ubiquitin aggregate clearance via
RT   autophagy.";
RL   Autophagy 6:614-621(2010).
RN   [22]
RP   FUNCTION, INTERACTION WITH SQSTM1, ACTIVITY REGULATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF ARG-380; ASN-382; ARG-415; HIS-436; ARG-483;
RP   TYR-525 AND TYR-572.
RX   PubMed=20452972; DOI=10.1074/jbc.m110.118976;
RA   Jain A., Lamark T., Sjoettem E., Larsen K.B., Awuh J.A., Oevervatn A.,
RA   McMahon M., Hayes J.D., Johansen T.;
RT   "p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a
RT   positive feedback loop by inducing antioxidant response element-driven gene
RT   transcription.";
RL   J. Biol. Chem. 285:22576-22591(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INTERACTION WITH SESN1 AND SESN2.
RX   PubMed=23274085; DOI=10.1016/j.cmet.2012.12.002;
RA   Bae S.H., Sung S.H., Oh S.Y., Lim J.M., Lee S.K., Park Y.N., Lee H.E.,
RA   Kang D., Rhee S.G.;
RT   "Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation
RT   of Keap1 and prevent oxidative liver damage.";
RL   Cell Metab. 17:73-84(2013).
RN   [25]
RP   INTERACTION WITH MAP1LC3B.
RX   PubMed=24089205; DOI=10.1038/nature12606;
RA   Tang Z., Lin M.G., Stowe T.R., Chen S., Zhu M., Stearns T., Franco B.,
RA   Zhong Q.;
RT   "Autophagy promotes primary ciliogenesis by removing OFD1 from centriolar
RT   satellites.";
RL   Nature 502:254-257(2013).
RN   [26]
RP   INTERACTION WITH HSP90AA1 AND HSP90AB1.
RX   PubMed=26517842; DOI=10.1371/journal.pone.0141786;
RA   Prince T.L., Kijima T., Tatokoro M., Lee S., Tsutsumi S., Yim K., Rivas C.,
RA   Alarcon S., Schwartz H., Khamit-Kush K., Scroggins B.T., Beebe K.,
RA   Trepel J.B., Neckers L.;
RT   "Client proteins and small molecule inhibitors display distinct binding
RT   preferences for constitutive and stress-induced HSP90 isoforms and their
RT   conformationally restricted mutants.";
RL   PLoS ONE 10:E0141786-E0141786(2015).
RN   [27]
RP   INTERACTION WITH EBOLAVIRUS PROTEIN VP24 (MICROBIAL INFECTION).
RX   PubMed=24630991; DOI=10.1016/j.celrep.2014.01.043;
RA   Edwards M.R., Johnson B., Mire C.E., Xu W., Shabman R.S., Speller L.N.,
RA   Leung D.W., Geisbert T.W., Amarasinghe G.K., Basler C.F.;
RT   "The Marburg virus VP24 protein interacts with Keap1 to activate the
RT   cytoprotective antioxidant response pathway.";
RL   Cell Rep. 6:1017-1025(2014).
RN   [28]
RP   FUNCTION.
RX   PubMed=28380357; DOI=10.1016/j.celrep.2017.03.030;
RA   Lee Y., Chou T.F., Pittman S.K., Keith A.L., Razani B., Weihl C.C.;
RT   "Keap1/cullin3 modulates p62/SQSTM1 activity via UBA domain
RT   ubiquitination.";
RL   Cell Rep. 19:188-202(2017).
RN   [29]
RP   FUNCTION, ALKYLATION AT CYS-151; CYS-257; CYS-273 AND CYS-288, ACTIVITY
RP   REGULATION, DOMAIN, AND MUTAGENESIS OF CYS-151.
RX   PubMed=29590092; DOI=10.1038/nature25986;
RA   Mills E.L., Ryan D.G., Prag H.A., Dikovskaya D., Menon D., Zaslona Z.,
RA   Jedrychowski M.P., Costa A.S.H., Higgins M., Hams E., Szpyt J.,
RA   Runtsch M.C., King M.S., McGouran J.F., Fischer R., Kessler B.M.,
RA   McGettrick A.F., Hughes M.M., Carroll R.G., Booty L.M., Knatko E.V.,
RA   Meakin P.J., Ashford M.L.J., Modis L.K., Brunori G., Sevin D.C.,
RA   Fallon P.G., Caldwell S.T., Kunji E.R.S., Chouchani E.T., Frezza C.,
RA   Dinkova-Kostova A.T., Hartley R.C., Murphy M.P., O'Neill L.A.;
RT   "Itaconate is an anti-inflammatory metabolite that activates Nrf2 via
RT   alkylation of KEAP1.";
RL   Nature 556:113-117(2018).
RN   [30]
RP   CROSS-LINK AT ARG-135 AND CYS-151, ACTIVITY REGULATION, DOMAIN, AND
RP   MUTAGENESIS OF ARG-15; ARG-135 AND CYS-151.
RX   PubMed=30323285; DOI=10.1038/s41586-018-0622-0;
RA   Bollong M.J., Lee G., Coukos J.S., Yun H., Zambaldo C., Chang J.W.,
RA   Chin E.N., Ahmad I., Chatterjee A.K., Lairson L.L., Schultz P.G.,
RA   Moellering R.E.;
RT   "A metabolite-derived protein modification integrates glycolysis with
RT   KEAP1-NRF2 signalling.";
RL   Nature 562:600-604(2018).
RN   [31]
RP   REVIEW.
RX   PubMed=28842501; DOI=10.1074/jbc.r117.800169;
RA   Suzuki T., Yamamoto M.;
RT   "Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2
RT   system during cellular stress.";
RL   J. Biol. Chem. 292:16817-16824(2017).
RN   [32]
RP   UBIQUITINATION.
RX   PubMed=31953436; DOI=10.1038/s41467-019-14190-2;
RA   Liu Y., Tao S., Liao L., Li Y., Li H., Li Z., Lin L., Wan X., Yang X.,
RA   Chen L.;
RT   "TRIM25 promotes the cell survival and growth of hepatocellular carcinoma
RT   through targeting Keap1-Nrf2 pathway.";
RL   Nat. Commun. 11:348-348(2020).
RN   [33]
RP   FUNCTION, AND DEUBIQUITINATION BY USP25.
RX   PubMed=37339955; DOI=10.1038/s41467-023-39412-6;
RA   Cai C., Ma H., Peng J., Shen X., Zhen X., Yu C., Zhang P., Ji F., Wang J.;
RT   "USP25 regulates KEAP1-NRF2 anti-oxidation axis and its inactivation
RT   protects acetaminophen-induced liver injury in male mice.";
RL   Nat. Commun. 14:3648-3648(2023).
RN   [34]
RP   INTERACTION WITH PGCKA1, AND MUTAGENESIS OF LYS-615.
RX   PubMed=36882524; DOI=10.1038/s41388-023-02656-z;
RA   Huang S., Li J., Wu S., Zheng Z., Wang C., Li H., Zhao L., Zhang X.,
RA   Huang H., Huang C., Xie Q.;
RT   "C4orf19 inhibits colorectal cancer cell proliferation by competitively
RT   binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis.";
RL   Oncogene 42:1333-1346(2023).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 321-609.
RX   PubMed=15583386; DOI=10.1107/s0907444904024825;
RA   Li X., Zhang D., Hannink M., Beamer L.J.;
RT   "Crystallization and initial crystallographic analysis of the Kelch domain
RT   from human Keap1.";
RL   Acta Crystallogr. D 60:2346-2348(2004).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 321-609.
RX   PubMed=16204884; DOI=10.1107/s0907444905022626;
RA   Beamer L.J., Li X., Bottoms C.A., Hannink M.;
RT   "Conserved solvent and side-chain interactions in the 1.35 Angstrom
RT   structure of the Kelch domain of Keap1.";
RL   Acta Crystallogr. D 61:1335-1342(2005).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 321-609 IN COMPLEX WITH NFE2L2,
RP   SUBUNIT, AND MUTAGENESIS OF TYR-334; ARG-380; ASN-382; ARG-415; HIS-436;
RP   PHE-478; ARG-483; TYR-525 AND TYR-572.
RX   PubMed=16888629; DOI=10.1038/sj.emboj.7601243;
RA   Lo S.-C., Li X., Henzl M.T., Beamer L.J., Hannink M.;
RT   "Structure of the Keap1:Nrf2 interface provides mechanistic insight into
RT   Nrf2 signaling.";
RL   EMBO J. 25:3605-3617(2006).
RN   [38] {ECO:0007744|PDB:4CXI, ECO:0007744|PDB:4CXJ, ECO:0007744|PDB:4CXT}
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 48-180, INTERACTION WITH CUL3,
RP   AND MUTAGENESIS OF CYS-151.
RX   PubMed=24896564; DOI=10.1371/journal.pone.0098896;
RA   Cleasby A., Yon J., Day P.J., Richardson C., Tickle I.J., Williams P.A.,
RA   Callahan J.F., Carr R., Concha N., Kerns J.K., Qi H., Sweitzer T., Ward P.,
RA   Davies T.G.;
RT   "Structure of the BTB domain of Keap1 and its interaction with the
RT   triterpenoid antagonist CDDO.";
RL   PLoS ONE 9:e98896-e98896(2014).
RN   [39]
RP   VARIANTS CYS-364 AND CYS-430, AND CHARACTERIZATION OF VARIANTS CYS-364 AND
RP   CYS-430.
RX   PubMed=16507366; DOI=10.1016/j.molcel.2006.01.013;
RA   Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M.,
RA   Kang M., Kobayashi A., Yokoyama S., Yamamoto M.;
RT   "Structural basis for defects of Keap1 activity provoked by its point
RT   mutations in lung cancer.";
RL   Mol. Cell 21:689-700(2006).
RN   [40]
RP   VARIANTS PHE-167; HIS-236; LEU-284; CYS-333 AND SER-350, AND
RP   CHARACTERIZATION OF VARIANTS HIS-236 AND CYS-333.
RX   PubMed=17020408; DOI=10.1371/journal.pmed.0030420;
RA   Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O.,
RA   Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V.,
RA   Biswal S.;
RT   "Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.";
RL   PLoS Med. 3:1865-1876(2006).
RN   [41]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-23 AND VAL-522.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3
CC       ubiquitin ligase complex that regulates the response to oxidative
CC       stress by targeting NFE2L2/NRF2 for ubiquitination (PubMed:14585973,
CC       PubMed:15379550, PubMed:15572695, PubMed:15601839, PubMed:15983046,
CC       PubMed:37339955). KEAP1 acts as a key sensor of oxidative and
CC       electrophilic stress: in normal conditions, the BCR(KEAP1) complex
CC       mediates ubiquitination and degradation of NFE2L2/NRF2, a transcription
CC       factor regulating expression of many cytoprotective genes
CC       (PubMed:15601839, PubMed:16006525). In response to oxidative stress,
CC       different electrophile metabolites trigger non-enzymatic covalent
CC       modifications of highly reactive cysteine residues in KEAP1, leading to
CC       inactivate the ubiquitin ligase activity of the BCR(KEAP1) complex,
CC       promoting NFE2L2/NRF2 nuclear accumulation and expression of phase II
CC       detoxifying enzymes (PubMed:16006525, PubMed:17127771, PubMed:18251510,
CC       PubMed:19489739, PubMed:29590092). In response to selective autophagy,
CC       KEAP1 is sequestered in inclusion bodies following its interaction with
CC       SQSTM1/p62, leading to inactivation of the BCR(KEAP1) complex and
CC       activation of NFE2L2/NRF2 (PubMed:20452972). The BCR(KEAP1) complex
CC       also mediates ubiquitination of SQSTM1/p62, increasing SQSTM1/p62
CC       sequestering activity and degradation (PubMed:28380357). The BCR(KEAP1)
CC       complex also targets BPTF and PGAM5 for ubiquitination and degradation
CC       by the proteasome (PubMed:15379550, PubMed:17046835).
CC       {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550,
CC       ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16006525,
CC       ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771,
CC       ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739,
CC       ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:28380357,
CC       ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:37339955}.
CC   -!- ACTIVITY REGULATION: Ubiquitin ligase activity of the BCR(KEAP1)
CC       complex is inhibited by oxidative stress and electrophile metabolites
CC       such as sulforaphane (PubMed:15983046, PubMed:17046835,
CC       PubMed:29590092, PubMed:30323285). Electrophile metabolites react with
CC       reactive cysteine residues in KEAP1 and trigger non-enzymatic covalent
CC       modifications of these cysteine residues, leading to inactivate the
CC       ubiquitin ligase activity of the BCR(KEAP1) complex (PubMed:17127771,
CC       PubMed:18251510, PubMed:19489739, PubMed:29590092, PubMed:30323285).
CC       Selective autophagy also inactivates the BCR(KEAP1) complex via
CC       interaction between KEAP1 and SQSTM1/p62, which sequesters the complex
CC       in inclusion bodies and promotes its degradation (PubMed:20452972,
CC       PubMed:20495340). {ECO:0000269|PubMed:15983046,
CC       ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:17127771,
CC       ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739,
CC       ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340,
CC       ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:14585973, ECO:0000269|PubMed:15379550,
CC       ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:15983046}.
CC   -!- SUBUNIT: Component of the BCR(KEAP1) E3 ubiquitin ligase complex, at
CC       least composed of 2 molecules of CUL3, 2 molecules of KEAP1, and RBX1
CC       (PubMed:15572695, PubMed:15601839, PubMed:15983046, PubMed:17127771,
CC       PubMed:18251510, PubMed:24896564). Interacts with NFE2L2/NRF2; the
CC       interaction is direct (PubMed:15379550, PubMed:15601839,
CC       PubMed:16006525, PubMed:16888629, PubMed:18387606). Forms a ternary
CC       complex with NFE2L2/NRF2 and PGAM5 (PubMed:17046835). Interacts with
CC       (phosphorylated) SQSTM1/p62; the interaction is direct and inactivates
CC       the BCR(KEAP1) complex by sequestering it in inclusion bodies,
CC       promoting its degradation (PubMed:20452972, PubMed:20495340). Interacts
CC       with NFE2L1 (PubMed:16687406). Interacts with BPTF and PTMA
CC       (PubMed:15657435). Interacts with MAP1LC3B (PubMed:24089205). Interacts
CC       indirectly with ENC1 (PubMed:19424503). Interacts with SESN1 and SESN2
CC       (PubMed:23274085). Interacts with HSP90AA1 and HSP90AB1
CC       (PubMed:26517842). Interacts with PGCKA1; this interaction prevents the
CC       ubiquitination of KEAP1 by TRIM25, thus protecting KEAP1 from
CC       degradation (PubMed:36882524). {ECO:0000269|PubMed:15379550,
CC       ECO:0000269|PubMed:15572695, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:15983046,
CC       ECO:0000269|PubMed:16006525, ECO:0000269|PubMed:16687406,
CC       ECO:0000269|PubMed:16888629, ECO:0000269|PubMed:17046835,
CC       ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510,
CC       ECO:0000269|PubMed:18387606, ECO:0000269|PubMed:19424503,
CC       ECO:0000269|PubMed:20452972, ECO:0000269|PubMed:20495340,
CC       ECO:0000269|PubMed:23274085, ECO:0000269|PubMed:24089205,
CC       ECO:0000269|PubMed:24896564, ECO:0000269|PubMed:26517842,
CC       ECO:0000269|PubMed:36882524}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with ebolavirus protein VP24;
CC       this interaction activates transcription factor NFE2L2/NRF2 by blocking
CC       its interaction with KEAP1. {ECO:0000269|PubMed:24630991}.
CC   -!- INTERACTION:
CC       Q14145; Q5JTC6: AMER1; NbExp=2; IntAct=EBI-751001, EBI-6169747;
CC       Q14145; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-751001, EBI-11954519;
CC       Q14145; P45381: ASPA; NbExp=4; IntAct=EBI-751001, EBI-750475;
CC       Q14145; O14525-2: ASTN1; NbExp=4; IntAct=EBI-751001, EBI-21977454;
CC       Q14145; A9UGY9: ATG5; NbExp=3; IntAct=EBI-751001, EBI-10175276;
CC       Q14145; Q9H1Y0: ATG5; NbExp=3; IntAct=EBI-751001, EBI-1047414;
CC       Q14145; Q2NKX9: C2orf68; NbExp=3; IntAct=EBI-751001, EBI-11603468;
CC       Q14145; Q9BWT7: CARD10; NbExp=3; IntAct=EBI-751001, EBI-3866279;
CC       Q14145; Q9NPC3: CCNB1IP1; NbExp=4; IntAct=EBI-751001, EBI-745269;
CC       Q14145; P02452: COL1A1; NbExp=3; IntAct=EBI-751001, EBI-982999;
CC       Q14145; P02458-1: COL2A1; NbExp=3; IntAct=EBI-751001, EBI-12375799;
CC       Q14145; P68400: CSNK2A1; NbExp=3; IntAct=EBI-751001, EBI-347804;
CC       Q14145; Q13618: CUL3; NbExp=5; IntAct=EBI-751001, EBI-456129;
CC       Q14145; Q9NX09: DDIT4; NbExp=3; IntAct=EBI-751001, EBI-715104;
CC       Q14145; Q9NY33: DPP3; NbExp=13; IntAct=EBI-751001, EBI-718333;
CC       Q14145; Q96JC9: EAF1; NbExp=3; IntAct=EBI-751001, EBI-769261;
CC       Q14145; Q6P6B1: ERICH5; NbExp=3; IntAct=EBI-751001, EBI-11343491;
CC       Q14145; P62495: ETF1; NbExp=8; IntAct=EBI-751001, EBI-750990;
CC       Q14145; Q6P1L5: FAM117B; NbExp=6; IntAct=EBI-751001, EBI-3893327;
CC       Q14145; Q14440: GPErik; NbExp=3; IntAct=EBI-751001, EBI-10232920;
CC       Q14145; Q8TDV0: GPR151; NbExp=3; IntAct=EBI-751001, EBI-11955647;
CC       Q14145; P28799: GRN; NbExp=3; IntAct=EBI-751001, EBI-747754;
CC       Q14145; A0A0C4DFT7: GYPA; NbExp=3; IntAct=EBI-751001, EBI-12044847;
CC       Q14145; B8Q183: GYPA; NbExp=4; IntAct=EBI-751001, EBI-10176190;
CC       Q14145; P02724: GYPA; NbExp=4; IntAct=EBI-751001, EBI-702665;
CC       Q14145; P05362: ICAM1; NbExp=3; IntAct=EBI-751001, EBI-1035358;
CC       Q14145; Q9BYX4: IFIH1; NbExp=3; IntAct=EBI-751001, EBI-6115771;
CC       Q14145; O14920: IKBKB; NbExp=6; IntAct=EBI-751001, EBI-81266;
CC       Q14145; Q4KMZ1: IQCC; NbExp=3; IntAct=EBI-751001, EBI-12206419;
CC       Q14145; P05107: ITGB2; NbExp=3; IntAct=EBI-751001, EBI-300173;
CC       Q14145; O95198: KLHL2; NbExp=7; IntAct=EBI-751001, EBI-746999;
CC       Q14145; Q8N4I8: KLHL3; NbExp=3; IntAct=EBI-751001, EBI-10230467;
CC       Q14145; Q9UH77: KLHL3; NbExp=5; IntAct=EBI-751001, EBI-8524663;
CC       Q14145; P62310: LSM3; NbExp=6; IntAct=EBI-751001, EBI-348239;
CC       Q14145; Q13257: MAD2L1; NbExp=8; IntAct=EBI-751001, EBI-78203;
CC       Q14145; O60336: MAPKBP1; NbExp=3; IntAct=EBI-751001, EBI-947402;
CC       Q14145; Q9BTE3-2: MCMBP; NbExp=3; IntAct=EBI-751001, EBI-9384556;
CC       Q14145; Q14494: NFE2L1; NbExp=28; IntAct=EBI-751001, EBI-2804436;
CC       Q14145; Q16236: NFE2L2; NbExp=39; IntAct=EBI-751001, EBI-2007911;
CC       Q14145; Q96TA1: NIBAN2; NbExp=9; IntAct=EBI-751001, EBI-2514593;
CC       Q14145; Q96HA8: NTAQ1; NbExp=3; IntAct=EBI-751001, EBI-741158;
CC       Q14145; Q9NZJ9: NUDT4; NbExp=3; IntAct=EBI-751001, EBI-4280066;
CC       Q14145; Q9UKX7: NUP50; NbExp=3; IntAct=EBI-751001, EBI-2371082;
CC       Q14145; Q8N573-5: OXR1; NbExp=3; IntAct=EBI-751001, EBI-10265887;
CC       Q14145; Q86YC2: PALB2; NbExp=6; IntAct=EBI-751001, EBI-1222653;
CC       Q14145; Q15149: PLEC; NbExp=3; IntAct=EBI-751001, EBI-297903;
CC       Q14145; P54619: PRKAG1; NbExp=6; IntAct=EBI-751001, EBI-1181439;
CC       Q14145; P06454-2: PTMA; NbExp=6; IntAct=EBI-751001, EBI-10194874;
CC       Q14145; Q6P9E2: RECK; NbExp=6; IntAct=EBI-751001, EBI-10253121;
CC       Q14145; Q04206: RELA; NbExp=4; IntAct=EBI-751001, EBI-73886;
CC       Q14145; P58004: SESN2; NbExp=3; IntAct=EBI-751001, EBI-3939642;
CC       Q14145; Q96GM5: SMARCD1; NbExp=3; IntAct=EBI-751001, EBI-358489;
CC       Q14145; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-751001, EBI-5235340;
CC       Q14145; Q13501: SQSTM1; NbExp=21; IntAct=EBI-751001, EBI-307104;
CC       Q14145; Q9UGK3: STAP2; NbExp=3; IntAct=EBI-751001, EBI-1553984;
CC       Q14145; Q9P0N9: TBC1D7; NbExp=3; IntAct=EBI-751001, EBI-3258000;
CC       Q14145; P54274: TERF1; NbExp=2; IntAct=EBI-751001, EBI-710997;
CC       Q14145; Q9Y3Q8: TSC22D4; NbExp=4; IntAct=EBI-751001, EBI-739485;
CC       Q14145; Q9BRX9: WDR83; NbExp=7; IntAct=EBI-751001, EBI-7705033;
CC       Q14145; O76024: WFS1; NbExp=3; IntAct=EBI-751001, EBI-720609;
CC       Q14145; Q9P202: WHRN; NbExp=3; IntAct=EBI-751001, EBI-310886;
CC       Q14145; P58317: ZNF121; NbExp=3; IntAct=EBI-751001, EBI-1228269;
CC       Q14145; Q9NX65: ZSCAN32; NbExp=3; IntAct=EBI-751001, EBI-739949;
CC       Q14145; O88351: Ikbkb; Xeno; NbExp=2; IntAct=EBI-751001, EBI-447960;
CC       Q14145; P15314: Irf1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-6115486;
CC       Q14145; Q64337: Sqstm1; Xeno; NbExp=2; IntAct=EBI-751001, EBI-645025;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14585973,
CC       ECO:0000269|PubMed:15379550, ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:15657435, ECO:0000269|PubMed:19424503}. Nucleus
CC       {ECO:0000269|PubMed:15657435}. Note=Mainly cytoplasmic
CC       (PubMed:15601839). In response to selective autophagy, relocalizes to
CC       inclusion bodies following interaction with SQSTM1/p62
CC       (PubMed:20452972). {ECO:0000269|PubMed:15601839,
CC       ECO:0000269|PubMed:20452972}.
CC   -!- TISSUE SPECIFICITY: Broadly expressed, with highest levels in skeletal
CC       muscle. {ECO:0000269|PubMed:15379550}.
CC   -!- DOMAIN: KEAP1 contains reactive cysteine residues that act as sensors
CC       for endogenously produced and exogenously encountered small molecules,
CC       which react with sulfhydryl groups and modify the cysteine sensors,
CC       leading to impair ability of the BCR(KEAP1) complex to ubiquitinate
CC       target proteins. {ECO:0000269|PubMed:17127771,
CC       ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739,
CC       ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285}.
CC   -!- DOMAIN: The Kelch repeats mediate interaction with NFE2L2/NRF2, BPTF
CC       and PGAM5. {ECO:0000269|PubMed:17046835}.
CC   -!- PTM: Non-enzymatic covalent modifications of reactive cysteines by
CC       electrophile metabolites inactivate the BCR(KEAP1) complex
CC       (PubMed:17127771, PubMed:18251510, PubMed:29590092, PubMed:30323285).
CC       Accumulation of fumarate promotes the formation of cysteine S-
CC       succination (S-(2-succinyl)cysteine), leading to inactivate the
CC       BCR(KEAP1) complex and promote NFE2L2/NRF2 nuclear accumulation and
CC       activation (By similarity). Nitric oxide-dependent 8-Nitro-cGMP
CC       formation promotes cysteine guanylation (S-cGMP-cysteine), leading to
CC       NFE2L2/NRF2 nuclear accumulation and activation (By similarity).
CC       Itaconate, an anti-inflammatory metabolite generated in response to
CC       lipopolysaccharide, alkylates cysteines, activating NFE2L2/NRF2
CC       (PubMed:29590092). Methylglyoxal, a reactive metabolite that
CC       accumulates when the glycolytic enzyme PGK1 is inhibited, promotes
CC       formation of a methylimidazole cross-link between proximal Cys-151 and
CC       Arg-135 on another KEAP1 molecule, resulting in an inactive dimer that
CC       inactivates the BCR(KEAP1) complex (PubMed:30323285).
CC       {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:17127771,
CC       ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:29590092,
CC       ECO:0000269|PubMed:30323285}.
CC   -!- PTM: Degraded via a proteasomal-independent process during selective
CC       autophagy: interaction with phosphorylated SQSTM1/p62 sequesters KEAP1
CC       in inclusion bodies, leading to its degradation.
CC       {ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:20452972}.
CC   -!- PTM: Auto-ubiquitinated by the BCR(KEAP1) complex (PubMed:15572695,
CC       PubMed:15983046). Quinone-induced oxidative stress, but not
CC       sulforaphane, increases its ubiquitination (PubMed:15572695,
CC       PubMed:15983046). Ubiquitination and subsequent degradation is most
CC       pronounced following prolonged exposure of cells to oxidative stress,
CC       particularly in glutathione-deficient cells that are highly susceptible
CC       to oxidative stress (PubMed:15572695, PubMed:15983046). Deubiquitinated
CC       by USP25; leading to stabilization (PubMed:37339955). Ubiquitinated by
CC       TRIM25; leading to degradation upon ER stress (PubMed:31953436,
CC       PubMed:36882524). {ECO:0000269|PubMed:15572695,
CC       ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:31953436,
CC       ECO:0000269|PubMed:36882524, ECO:0000269|PubMed:37339955}.
CC   -!- SIMILARITY: Belongs to the KEAP1 family. {ECO:0000305}.
CC   -!- CAUTION: The mechanism of inactivation of the BCR(KEAP1) complex by
CC       covalent modifications of reactive cysteines is unclear. Covalent
CC       modifications were initially thought to disrupt interaction between
CC       KEAP1 and NFE2L2/NRF2 (By similarity). Recent publications suggest that
CC       cysteine modifications disrupt the interaction between KEAP1 and CUL3
CC       without affecting the interaction between KEAP1 and NFE2L2/NRF2
CC       (PubMed:16006525, PubMed:17127771, PubMed:18251510, PubMed:24896564).
CC       {ECO:0000250|UniProtKB:Q9Z2X8, ECO:0000269|PubMed:16006525,
CC       ECO:0000269|PubMed:17127771, ECO:0000269|PubMed:18251510,
CC       ECO:0000269|PubMed:24896564}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09481.3; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF361892; AAK43722.1; -; Genomic_DNA.
DR   EMBL; AF361888; AAK43722.1; JOINED; Genomic_DNA.
DR   EMBL; AF361889; AAK43722.1; JOINED; Genomic_DNA.
DR   EMBL; AF361890; AAK43722.1; JOINED; Genomic_DNA.
DR   EMBL; AF361891; AAK43722.1; JOINED; Genomic_DNA.
DR   EMBL; AF361886; AAK51082.1; -; mRNA.
DR   EMBL; D50922; BAA09481.3; ALT_INIT; mRNA.
DR   EMBL; AK056204; BAG51647.1; -; mRNA.
DR   EMBL; AC011461; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002417; AAH02417.1; -; mRNA.
DR   EMBL; BC002930; AAH02930.1; -; mRNA.
DR   EMBL; BC015945; AAH15945.1; -; mRNA.
DR   EMBL; BC021957; AAH21957.2; -; mRNA.
DR   CCDS; CCDS12239.1; -.
DR   RefSeq; NP_036421.2; NM_012289.3.
DR   RefSeq; NP_987096.1; NM_203500.2.
DR   RefSeq; XP_005260230.1; XM_005260173.1.
DR   RefSeq; XP_005260231.1; XM_005260174.1.
DR   RefSeq; XP_011526754.1; XM_011528452.1.
DR   PDB; 1U6D; X-ray; 1.85 A; X=321-609.
DR   PDB; 1ZGK; X-ray; 1.35 A; A=321-609.
DR   PDB; 2FLU; X-ray; 1.50 A; X=321-609.
DR   PDB; 3VNG; X-ray; 2.10 A; A=321-609.
DR   PDB; 3VNH; X-ray; 2.10 A; A=321-609.
DR   PDB; 3ZGC; X-ray; 2.20 A; A/B=321-609.
DR   PDB; 3ZGD; X-ray; 1.98 A; A/B=321-609.
DR   PDB; 4CXI; X-ray; 2.35 A; A=48-180.
DR   PDB; 4CXJ; X-ray; 2.80 A; A=48-180.
DR   PDB; 4CXT; X-ray; 2.66 A; A=48-180.
DR   PDB; 4IFJ; X-ray; 1.80 A; A=321-609.
DR   PDB; 4IFL; X-ray; 1.80 A; X=321-609.
DR   PDB; 4IFN; X-ray; 2.40 A; X=321-609.
DR   PDB; 4IN4; X-ray; 2.59 A; A/B/C=321-609.
DR   PDB; 4IQK; X-ray; 1.97 A; A=321-609.
DR   PDB; 4L7B; X-ray; 2.41 A; A/B=321-609.
DR   PDB; 4L7C; X-ray; 2.40 A; A/B/C=321-609.
DR   PDB; 4L7D; X-ray; 2.25 A; A/B/C=321-609.
DR   PDB; 4N1B; X-ray; 2.55 A; A/B/C=321-609.
DR   PDB; 4XMB; X-ray; 2.43 A; A=321-609.
DR   PDB; 5DAD; X-ray; 2.61 A; A=49-182.
DR   PDB; 5DAF; X-ray; 2.37 A; A=49-182.
DR   PDB; 5F72; X-ray; 1.85 A; C/K=321-611.
DR   PDB; 5GIT; X-ray; 2.19 A; A=48-180.
DR   PDB; 5NLB; X-ray; 3.45 A; A=51-204.
DR   PDB; 5WFL; X-ray; 1.93 A; A/B=312-624.
DR   PDB; 5WFV; X-ray; 1.91 A; A/B=320-612.
DR   PDB; 5WG1; X-ray; 2.02 A; A/B=320-612.
DR   PDB; 5WHL; X-ray; 2.50 A; A/B=312-624.
DR   PDB; 5WHO; X-ray; 2.23 A; A/B=312-624.
DR   PDB; 5WIY; X-ray; 2.23 A; A/B=312-624.
DR   PDB; 5X54; X-ray; 2.30 A; A/B=321-609.
DR   PDB; 6FFM; X-ray; 2.20 A; A=48-180.
DR   PDB; 6FMP; X-ray; 2.92 A; A/B=321-609.
DR   PDB; 6FMQ; X-ray; 2.10 A; A/B=321-609.
DR   PDB; 6HWS; X-ray; 1.75 A; A=321-609.
DR   PDB; 6LRZ; X-ray; 1.54 A; A=311-616.
DR   PDB; 6ROG; X-ray; 2.16 A; A/X=321-609.
DR   PDB; 6SP1; X-ray; 2.57 A; A/B=321-609.
DR   PDB; 6SP4; X-ray; 2.59 A; A/B/C/D/E/F=321-609.
DR   PDB; 6T7V; X-ray; 2.60 A; A=321-609.
DR   PDB; 6T7Z; X-ray; 2.00 A; A=321-609.
DR   PDB; 6TG8; X-ray; 2.75 A; AAA=322-609.
DR   PDB; 6TYM; X-ray; 1.42 A; A=321-609.
DR   PDB; 6TYP; X-ray; 2.50 A; A=321-609.
DR   PDB; 6UF0; X-ray; 1.96 A; A/B=321-609.
DR   PDB; 6V6Z; X-ray; 1.60 A; A/B/C/D=321-609.
DR   PDB; 6W66; X-ray; 3.21 A; C=48-180.
DR   PDB; 6W67; X-ray; 2.20 A; A=48-180.
DR   PDB; 6W68; X-ray; 2.55 A; A=48-180.
DR   PDB; 6W69; X-ray; 2.50 A; A=48-180.
DR   PDB; 6WCQ; EM; 8.50 A; C=1-624.
DR   PDB; 6Z6A; X-ray; 2.37 A; A/B=321-609.
DR   PDB; 7EXI; X-ray; 1.82 A; A=45-180.
DR   PDB; 7K28; X-ray; 2.15 A; A/B=325-614.
DR   PDB; 7K29; X-ray; 2.20 A; A/B=324-624.
DR   PDB; 7K2A; X-ray; 1.90 A; A/B=324-624.
DR   PDB; 7K2B; X-ray; 2.31 A; A/B=324-624.
DR   PDB; 7K2C; X-ray; 2.11 A; A/B=325-614.
DR   PDB; 7K2D; X-ray; 2.21 A; A/B=324-623.
DR   PDB; 7K2E; X-ray; 2.03 A; A/B=324-624.
DR   PDB; 7K2F; X-ray; 2.37 A; A/X=312-623.
DR   PDB; 7K2G; X-ray; 2.15 A; A/B=324-624.
DR   PDB; 7K2H; X-ray; 2.09 A; A/B=324-624.
DR   PDB; 7K2I; X-ray; 2.42 A; A/B=324-623.
DR   PDB; 7K2J; X-ray; 2.52 A; A/B=325-614.
DR   PDB; 7K2K; X-ray; 1.98 A; A/B=324-624.
DR   PDB; 7K2L; X-ray; 1.98 A; A=326-609, B=326-614.
DR   PDB; 7K2M; X-ray; 2.02 A; A/B=326-614.
DR   PDB; 7K2N; X-ray; 2.22 A; A/B=324-624.
DR   PDB; 7K2O; X-ray; 2.11 A; A/B=324-624.
DR   PDB; 7K2P; X-ray; 2.11 A; A/B=324-624.
DR   PDB; 7K2Q; X-ray; 2.37 A; A/B=325-614.
DR   PDB; 7K2R; X-ray; 2.10 A; A/B=325-614.
DR   PDB; 7K2S; X-ray; 2.13 A; A/B=324-624.
DR   PDB; 7Q5H; X-ray; 2.31 A; A/B=321-609.
DR   PDB; 7Q6Q; X-ray; 2.55 A; A/B=321-609.
DR   PDB; 7Q6S; X-ray; 2.14 A; A/B=321-609.
DR   PDB; 7Q8R; X-ray; 2.28 A; A/B=321-609.
DR   PDB; 7Q96; X-ray; 2.42 A; A/B=321-609.
DR   PDB; 7X4W; X-ray; 3.21 A; A/B/C/D/E/F=48-180.
DR   PDB; 7X4X; X-ray; 2.96 A; A/B/C/D/E/F=48-180.
DR   PDB; 7XM2; X-ray; 2.30 A; X=321-609.
DR   PDB; 7XM3; X-ray; 2.80 A; A=321-609.
DR   PDB; 7XM4; X-ray; 2.70 A; A=321-609.
DR   PDB; 7XM5; X-ray; 2.40 A; A=321-609.
DR   PDB; 7XOT; X-ray; 2.70 A; A=321-609.
DR   PDB; 8EHV; X-ray; 2.29 A; A/B=312-624.
DR   PDB; 8EJR; X-ray; 2.08 A; A/B=312-624.
DR   PDB; 8EJS; X-ray; 2.82 A; A/B=312-624.
DR   PDB; 8IVG; X-ray; 1.80 A; A=310-624.
DR   PDB; 8IVR; X-ray; 1.50 A; A=310-624.
DR   PDB; 8IXS; X-ray; 1.48 A; A=310-624.
DR   PDB; 8PKS; X-ray; 2.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N=471-609.
DR   PDB; 8PKU; X-ray; 1.73 A; A/B=312-623.
DR   PDB; 8PKV; X-ray; 1.55 A; A/B=312-623.
DR   PDB; 8PKW; X-ray; 1.54 A; A/B=312-623.
DR   PDB; 8PKX; X-ray; 1.79 A; A/B=312-623.
DR   PDB; 8WFG; X-ray; 2.25 A; A=48-180.
DR   PDB; 8X34; X-ray; 2.80 A; A/B=324-609.
DR   PDB; 8XGK; X-ray; 1.32 A; A=310-624.
DR   PDB; 8XGV; X-ray; 1.42 A; A=310-624.
DR   PDB; 9DU7; X-ray; 1.87 A; A/B=48-180.
DR   PDB; 9ETX; X-ray; 2.34 A; A/B=48-213.
DR   PDB; 9ETY; X-ray; 1.87 A; A/B=48-213.
DR   PDBsum; 1U6D; -.
DR   PDBsum; 1ZGK; -.
DR   PDBsum; 2FLU; -.
DR   PDBsum; 3VNG; -.
DR   PDBsum; 3VNH; -.
DR   PDBsum; 3ZGC; -.
DR   PDBsum; 3ZGD; -.
DR   PDBsum; 4CXI; -.
DR   PDBsum; 4CXJ; -.
DR   PDBsum; 4CXT; -.
DR   PDBsum; 4IFJ; -.
DR   PDBsum; 4IFL; -.
DR   PDBsum; 4IFN; -.
DR   PDBsum; 4IN4; -.
DR   PDBsum; 4IQK; -.
DR   PDBsum; 4L7B; -.
DR   PDBsum; 4L7C; -.
DR   PDBsum; 4L7D; -.
DR   PDBsum; 4N1B; -.
DR   PDBsum; 4XMB; -.
DR   PDBsum; 5DAD; -.
DR   PDBsum; 5DAF; -.
DR   PDBsum; 5F72; -.
DR   PDBsum; 5GIT; -.
DR   PDBsum; 5NLB; -.
DR   PDBsum; 5WFL; -.
DR   PDBsum; 5WFV; -.
DR   PDBsum; 5WG1; -.
DR   PDBsum; 5WHL; -.
DR   PDBsum; 5WHO; -.
DR   PDBsum; 5WIY; -.
DR   PDBsum; 5X54; -.
DR   PDBsum; 6FFM; -.
DR   PDBsum; 6FMP; -.
DR   PDBsum; 6FMQ; -.
DR   PDBsum; 6HWS; -.
DR   PDBsum; 6LRZ; -.
DR   PDBsum; 6ROG; -.
DR   PDBsum; 6SP1; -.
DR   PDBsum; 6SP4; -.
DR   PDBsum; 6T7V; -.
DR   PDBsum; 6T7Z; -.
DR   PDBsum; 6TG8; -.
DR   PDBsum; 6TYM; -.
DR   PDBsum; 6TYP; -.
DR   PDBsum; 6UF0; -.
DR   PDBsum; 6V6Z; -.
DR   PDBsum; 6W66; -.
DR   PDBsum; 6W67; -.
DR   PDBsum; 6W68; -.
DR   PDBsum; 6W69; -.
DR   PDBsum; 6WCQ; -.
DR   PDBsum; 6Z6A; -.
DR   PDBsum; 7EXI; -.
DR   PDBsum; 7K28; -.
DR   PDBsum; 7K29; -.
DR   PDBsum; 7K2A; -.
DR   PDBsum; 7K2B; -.
DR   PDBsum; 7K2C; -.
DR   PDBsum; 7K2D; -.
DR   PDBsum; 7K2E; -.
DR   PDBsum; 7K2F; -.
DR   PDBsum; 7K2G; -.
DR   PDBsum; 7K2H; -.
DR   PDBsum; 7K2I; -.
DR   PDBsum; 7K2J; -.
DR   PDBsum; 7K2K; -.
DR   PDBsum; 7K2L; -.
DR   PDBsum; 7K2M; -.
DR   PDBsum; 7K2N; -.
DR   PDBsum; 7K2O; -.
DR   PDBsum; 7K2P; -.
DR   PDBsum; 7K2Q; -.
DR   PDBsum; 7K2R; -.
DR   PDBsum; 7K2S; -.
DR   PDBsum; 7Q5H; -.
DR   PDBsum; 7Q6Q; -.
DR   PDBsum; 7Q6S; -.
DR   PDBsum; 7Q8R; -.
DR   PDBsum; 7Q96; -.
DR   PDBsum; 7X4W; -.
DR   PDBsum; 7X4X; -.
DR   PDBsum; 7XM2; -.
DR   PDBsum; 7XM3; -.
DR   PDBsum; 7XM4; -.
DR   PDBsum; 7XM5; -.
DR   PDBsum; 7XOT; -.
DR   PDBsum; 8EHV; -.
DR   PDBsum; 8EJR; -.
DR   PDBsum; 8EJS; -.
DR   PDBsum; 8IVG; -.
DR   PDBsum; 8IVR; -.
DR   PDBsum; 8IXS; -.
DR   PDBsum; 8PKS; -.
DR   PDBsum; 8PKU; -.
DR   PDBsum; 8PKV; -.
DR   PDBsum; 8PKW; -.
DR   PDBsum; 8PKX; -.
DR   PDBsum; 8WFG; -.
DR   PDBsum; 8X34; -.
DR   PDBsum; 8XGK; -.
DR   PDBsum; 8XGV; -.
DR   PDBsum; 9DU7; -.
DR   PDBsum; 9ETX; -.
DR   PDBsum; 9ETY; -.
DR   AlphaFoldDB; Q14145; -.
DR   BMRB; Q14145; -.
DR   EMDB; EMD-21617; -.
DR   SMR; Q14145; -.
DR   BioGRID; 115156; 359.
DR   ComplexPortal; CPX-8107; CRL3 E3 ubiquitin ligase complex, KEAP1 variant.
DR   CORUM; Q14145; -.
DR   DIP; DIP-42134N; -.
DR   ELM; Q14145; -.
DR   FunCoup; Q14145; 673.
DR   IntAct; Q14145; 200.
DR   MINT; Q14145; -.
DR   STRING; 9606.ENSP00000377245; -.
DR   BindingDB; Q14145; -.
DR   ChEMBL; CHEMBL2069156; -.
DR   DrugBank; DB04339; Carbocisteine.
DR   DrugBank; DB08908; Dimethyl fumarate.
DR   DrugBank; DB12513; Omaveloxolone.
DR   DrugCentral; Q14145; -.
DR   GuidetoPHARMACOLOGY; 2757; -.
DR   GlyCosmos; Q14145; 11 sites, 1 glycan.
DR   GlyGen; Q14145; 18 sites, 1 O-linked glycan (11 sites).
DR   iPTMnet; Q14145; -.
DR   PhosphoSitePlus; Q14145; -.
DR   SwissPalm; Q14145; -.
DR   BioMuta; KEAP1; -.
DR   DMDM; 146345444; -.
DR   jPOST; Q14145; -.
DR   MassIVE; Q14145; -.
DR   PaxDb; 9606-ENSP00000171111; -.
DR   PeptideAtlas; Q14145; -.
DR   ProteomicsDB; 59849; -.
DR   Pumba; Q14145; -.
DR   ABCD; Q14145; 8 sequenced antibodies.
DR   Antibodypedia; 1418; 708 antibodies from 39 providers.
DR   DNASU; 9817; -.
DR   Ensembl; ENST00000171111.10; ENSP00000171111.4; ENSG00000079999.14.
DR   Ensembl; ENST00000393623.6; ENSP00000377245.1; ENSG00000079999.14.
DR   GeneID; 9817; -.
DR   KEGG; hsa:9817; -.
DR   MANE-Select; ENST00000171111.10; ENSP00000171111.4; NM_203500.2; NP_987096.1.
DR   UCSC; uc002moq.2; human.
DR   AGR; HGNC:23177; -.
DR   CTD; 9817; -.
DR   DisGeNET; 9817; -.
DR   GeneCards; KEAP1; -.
DR   HGNC; HGNC:23177; KEAP1.
DR   HPA; ENSG00000079999; Tissue enhanced (skeletal).
DR   MalaCards; KEAP1; -.
DR   MIM; 606016; gene.
DR   OpenTargets; ENSG00000079999; -.
DR   Orphanet; 276399; Familial multinodular goiter.
DR   VEuPathDB; HostDB:ENSG00000079999; -.
DR   eggNOG; KOG4441; Eukaryota.
DR   GeneTree; ENSGT00940000159543; -.
DR   HOGENOM; CLU_004253_14_2_1; -.
DR   InParanoid; Q14145; -.
DR   OMA; TECLTEY; -.
DR   OrthoDB; 45365at2759; -.
DR   PAN-GO; Q14145; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; Q14145; -.
DR   PathwayCommons; Q14145; -.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   Reactome; R-HSA-9759194; Nuclear events mediated by NFE2L2.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q14145; -.
DR   SIGNOR; Q14145; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 9817; 194 hits in 1230 CRISPR screens.
DR   CD-CODE; 5D6181E1; Synthetic Condensate 000293.
DR   CD-CODE; DEE660B4; Stress granule.
DR   CD-CODE; FBAE0D06; Synthetic Condensate 000291.
DR   ChiTaRS; KEAP1; human.
DR   EvolutionaryTrace; Q14145; -.
DR   GeneWiki; KEAP1; -.
DR   GenomeRNAi; 9817; -.
DR   Pharos; Q14145; Tclin.
DR   PRO; PR:Q14145; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q14145; protein.
DR   Bgee; ENSG00000079999; Expressed in hindlimb stylopod muscle and 201 other cell types or tissues.
DR   ExpressionAtlas; Q14145; baseline and differential.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0034451; C:centriolar satellite; IDA:HPA.
DR   GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0016234; C:inclusion body; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0097718; F:disordered domain specific binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990756; F:ubiquitin-like ligase-substrate adaptor activity; IDA:UniProt.
DR   GO; GO:0071353; P:cellular response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:1902883; P:negative regulation of response to oxidative stress; IDA:UniProt.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IDA:UniProt.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; IDA:UniProtKB.
DR   GO; GO:0045604; P:regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd18458; BACK_KLHL19_KEAP1; 1.
DR   CDD; cd18248; BTB_POZ_KLHL19_KEAP1; 1.
DR   FunFam; 2.120.10.80:FF:000024; Kelch-like ECH-associated protein 1; 1.
DR   FunFam; 1.25.40.420:FF:000001; Kelch-like family member 12; 1.
DR   FunFam; 3.30.710.10:FF:000001; Kelch-like family member 20; 1.
DR   Gene3D; 1.25.40.420; -; 1.
DR   Gene3D; 2.120.10.80; Kelch-type beta propeller; 1.
DR   Gene3D; 3.30.710.10; Potassium Channel Kv1.1, Chain A; 1.
DR   IDEAL; IID00384; -.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR017096; BTB-kelch_protein.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR047098; KEAP1_BACK.
DR   InterPro; IPR030563; KEAP1_BTB_POZ_dom.
DR   InterPro; IPR015915; Kelch-typ_b-propeller.
DR   InterPro; IPR006652; Kelch_1.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR24412; KELCH PROTEIN; 1.
DR   PANTHER; PTHR24412:SF162; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; 1.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF01344; Kelch_1; 3.
DR   Pfam; PF24681; Kelch_KLHDC2_KLHL20_DRC7; 1.
DR   PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00612; Kelch; 6.
DR   SUPFAM; SSF117281; Kelch motif; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
DR   neXtProt; NX_Q14145; -.
DR   PharmGKB; PA134887774; -.
DR   TreeFam; TF329218; -.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Host-virus interaction; Kelch repeat; Nucleus;
KW   Proteomics identification; Reference proteome; Repeat; S-nitrosylation;
KW   Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN           1..624
FT                   /note="Kelch-like ECH-associated protein 1"
FT                   /id="PRO_0000119093"
FT   DOMAIN          77..149
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   DOMAIN          184..286
FT                   /note="BACK"
FT   REPEAT          327..372
FT                   /note="Kelch 1"
FT   REPEAT          373..423
FT                   /note="Kelch 2"
FT   REPEAT          424..470
FT                   /note="Kelch 3"
FT   REPEAT          471..517
FT                   /note="Kelch 4"
FT   REPEAT          518..564
FT                   /note="Kelch 5"
FT   REPEAT          565..611
FT                   /note="Kelch 6"
FT   SITE            151
FT                   /note="Sensor for electrophilic agents"
FT                   /evidence="ECO:0000269|PubMed:18251510,
FT                   ECO:0000269|PubMed:29590092"
FT   SITE            257
FT                   /note="Sensor for electrophilic agents"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   SITE            273
FT                   /note="Sensor for electrophilic agents"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   SITE            288
FT                   /note="Sensor for electrophilic agents"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   SITE            434
FT                   /note="Sensor for electrophilic agents"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         38
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         151
FT                   /note="S-(2,3-dicarboxypropyl)cysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   MOD_RES         151
FT                   /note="S-(2-succinyl)cysteine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         151
FT                   /note="S-nitrosocysteine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         241
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         257
FT                   /note="S-(2,3-dicarboxypropyl)cysteine"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   MOD_RES         273
FT                   /note="S-(2,3-dicarboxypropyl)cysteine"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   MOD_RES         288
FT                   /note="S-(2,3-dicarboxypropyl)cysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:29590092"
FT   MOD_RES         288
FT                   /note="S-(2-succinyl)cysteine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         319
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         434
FT                   /note="S-cGMP-cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   MOD_RES         613
FT                   /note="S-(2-succinyl)cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2X8"
FT   CROSSLNK        135
FT                   /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-
FT                   ornithine (Arg-Cys) (interchain with C-151 in KEAP1)"
FT                   /evidence="ECO:0000269|PubMed:30323285"
FT   CROSSLNK        151
FT                   /note="N5-[4-(S-L-cysteinyl)-5-methyl-1H-imidazol-2-yl]-L-
FT                   ornithine (Cys-Arg) (interchain with R-135 in KEAP1)"
FT                   /evidence="ECO:0000269|PubMed:30323285"
FT   VARIANT         23
FT                   /note="C -> Y (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036084"
FT   VARIANT         167
FT                   /note="V -> F (in a lung adenocarcinoma patient)"
FT                   /evidence="ECO:0000269|PubMed:17020408"
FT                   /id="VAR_032102"
FT   VARIANT         236
FT                   /note="D -> H (in a NSCLC cell line)"
FT                   /evidence="ECO:0000269|PubMed:17020408"
FT                   /id="VAR_032103"
FT   VARIANT         284
FT                   /note="Q -> L (in a lung adenocarcinoma patient)"
FT                   /evidence="ECO:0000269|PubMed:17020408"
FT                   /id="VAR_032104"
FT   VARIANT         333
FT                   /note="G -> C (in a NSCLC cell line; strongly reduces
FT                   interaction with NFE2L2/NRF2 and reduces repression of
FT                   NFE2L2/NRF2-dependent gene expression)"
FT                   /evidence="ECO:0000269|PubMed:17020408"
FT                   /id="VAR_032105"
FT   VARIANT         349
FT                   /note="D -> N (in dbSNP:rs1048289)"
FT                   /evidence="ECO:0000269|PubMed:8590280"
FT                   /id="VAR_032106"
FT   VARIANT         350
FT                   /note="G -> S (in a NSCLC cell line; dbSNP:rs777308626)"
FT                   /evidence="ECO:0000269|PubMed:17020408"
FT                   /id="VAR_032107"
FT   VARIANT         364
FT                   /note="G -> C (in a lung adenocarcinoma cell line; also in
FT                   NSCLC cell lines; strongly reduces interaction with
FT                   NFE2L2/NRF2 and reduces repression of NFE2L2/NRF2-dependent
FT                   gene expression; dbSNP:rs1397945617)"
FT                   /evidence="ECO:0000269|PubMed:16507366"
FT                   /id="VAR_032108"
FT   VARIANT         430
FT                   /note="G -> C (in a lung adenocarcinoma patient; somatic
FT                   mutation; strongly reduces interaction with NFE2L2/NRF2 and
FT                   reduces repression of NFE2L2/NRF2-dependent gene
FT                   expression)"
FT                   /evidence="ECO:0000269|PubMed:16507366"
FT                   /id="VAR_032109"
FT   VARIANT         522
FT                   /note="A -> V (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036085"
FT   MUTAGEN         15
FT                   /note="R->A: Reduced formation of a high-molecular mass
FT                   KEAP1 molecule when methylglyoxal accumulates."
FT                   /evidence="ECO:0000269|PubMed:30323285"
FT   MUTAGEN         123..127
FT                   /note="VSIEG->ASAEA: Abolished interaction with
FT                   NFE2L2/NRF2; when associated with 161-A-A-162."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         125..127
FT                   /note="IEG->AAA: Increases ubiquitination and proteolytic
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:15572695"
FT   MUTAGEN         135
FT                   /note="R->A: Reduced formation of a high-molecular mass
FT                   KEAP1 molecule when methylglyoxal accumulates."
FT                   /evidence="ECO:0000269|PubMed:30323285"
FT   MUTAGEN         151
FT                   /note="C->S,N,D,L: Substitution with a small side chain
FT                   that prevents covalent modification by an electrophile;
FT                   promotes constitutive ubiquitination of NFE2L2/NRF2 and
FT                   subsequent repression of phase 2 detoxifying enzymes.
FT                   Resistance of ubiquitination of PGAM5 to inhibition by
FT                   oxidative stress and sulforaphane. Impaired interaction
FT                   with CUL3. Reduced formation of a high-molecular mass KEAP1
FT                   molecule when methylglyoxal accumulates."
FT                   /evidence="ECO:0000269|PubMed:14585973,
FT                   ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:17046835,
FT                   ECO:0000269|PubMed:18251510, ECO:0000269|PubMed:19489739,
FT                   ECO:0000269|PubMed:29590092, ECO:0000269|PubMed:30323285"
FT   MUTAGEN         151
FT                   /note="C->W,Y: Substitution with a bulky side chain that
FT                   mimicks covalent modification by an electrophile; prevents
FT                   ubiquitination and degradation of NFE2L2/NRF2, leading to
FT                   constitutive activation of NFE2L2/NRF2 and subsequent
FT                   expression of phase 2 detoxifying enzymes."
FT                   /evidence="ECO:0000269|PubMed:19489739,
FT                   ECO:0000269|PubMed:24896564"
FT   MUTAGEN         161..162
FT                   /note="MY->AA: Abolished interaction with NFE2L2/NRF2; when
FT                   associated with 123-A--A-127."
FT                   /evidence="ECO:0000269|PubMed:15601839"
FT   MUTAGEN         162..164
FT                   /note="YQI->AAA: Increases ubiquitination and proteolytic
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:15572695"
FT   MUTAGEN         273
FT                   /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent
FT                   gene expression. Slows down degradation of NFE2L2/NRF2."
FT                   /evidence="ECO:0000269|PubMed:14585973"
FT   MUTAGEN         288
FT                   /note="C->S: Abolishes repression of NFE2L2/NRF2-dependent
FT                   gene expression. Slows down degradation of NFE2L2/NRF2."
FT                   /evidence="ECO:0000269|PubMed:14585973"
FT   MUTAGEN         308
FT                   /note="L->A: Loss of export from nucleus; when associated
FT                   with A-310."
FT                   /evidence="ECO:0000269|PubMed:15657435"
FT   MUTAGEN         310
FT                   /note="L->A: Loss of export from nucleus; when associated
FT                   with A-308."
FT                   /evidence="ECO:0000269|PubMed:15657435"
FT   MUTAGEN         334
FT                   /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly
FT                   reduces repression of NFE2L2/NRF2-dependent gene
FT                   expression. Loss of interaction with PGAM5."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:17046835"
FT   MUTAGEN         380
FT                   /note="R->A: Loss of interaction with NFE2L2/NRF2.
FT                   Abolishes repression of NFE2L2/NRF2-dependent gene
FT                   expression. Impaired interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:20452972"
FT   MUTAGEN         382
FT                   /note="N->A: Loss of interaction with NFE2L2/NRF2. Strongly
FT                   reduces repression of NFE2L2/NRF2-dependent gene
FT                   expression. Impaired interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:20452972"
FT   MUTAGEN         415
FT                   /note="R->A: Loss of interaction with NFE2L2/NRF2.
FT                   Abolishes repression of NFE2L2/NRF2-dependent gene
FT                   expression. Loss of interaction with PGAM5. Does not affect
FT                   interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972"
FT   MUTAGEN         436
FT                   /note="H->A: Loss of interaction with NFE2L2/NRF2.
FT                   Abolishes repression of NFE2L2/NRF2-dependent gene
FT                   expression. Does not affect interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:20452972"
FT   MUTAGEN         478
FT                   /note="F->A: Abolishes repression of NFE2L2/NRF2-dependent
FT                   gene expression."
FT                   /evidence="ECO:0000269|PubMed:16888629"
FT   MUTAGEN         483
FT                   /note="R->A: Loss of interaction with NFE2L2/NRF2.
FT                   Abolishes repression of NFE2L2/NRF2-dependent gene
FT                   expression. Loss of interaction with PGAM5. Does not affect
FT                   interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972"
FT   MUTAGEN         525
FT                   /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly
FT                   reduces repression of NFE2L2/NRF2-dependent gene
FT                   expression. Abolishes interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:20452972"
FT   MUTAGEN         572
FT                   /note="Y->A: Loss of interaction with NFE2L2/NRF2. Strongly
FT                   reduces repression of NFE2L2/NRF2-dependent gene
FT                   expression. Loss of interaction with PGAM5. Abolishes
FT                   interaction with SQSTM1/p62."
FT                   /evidence="ECO:0000269|PubMed:16888629,
FT                   ECO:0000269|PubMed:17046835, ECO:0000269|PubMed:20452972"
FT   MUTAGEN         615
FT                   /note="K->R: Decreases binding to PGCKA1. Increases protein
FT                   half-life."
FT                   /evidence="ECO:0000269|PubMed:36882524"
FT   CONFLICT        504
FT                   /note="N -> S (in Ref. 4; BAG51647)"
FT                   /evidence="ECO:0000305"
FT   STRAND          51..55
FT                   /evidence="ECO:0007829|PDB:7X4X"
FT   HELIX           59..72
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   STRAND          79..83
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:5DAD"
FT   STRAND          91..95
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   HELIX           97..103
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   HELIX           105..111
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   STRAND          113..115
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   STRAND          116..119
FT                   /evidence="ECO:0007829|PDB:7X4W"
FT   STRAND          121..125
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   HELIX           130..142
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   STRAND          143..148
FT                   /evidence="ECO:0007829|PDB:7X4X"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   HELIX           152..161
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   HELIX           165..177
FT                   /evidence="ECO:0007829|PDB:7EXI"
FT   TURN            181..183
FT                   /evidence="ECO:0007829|PDB:5NLB"
FT   HELIX           184..194
FT                   /evidence="ECO:0007829|PDB:5NLB"
FT   HELIX           199..202
FT                   /evidence="ECO:0007829|PDB:5NLB"
FT   STRAND          327..331
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          334..338
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          342..345
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            347..349
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          352..354
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          362..364
FT                   /evidence="ECO:0007829|PDB:2FLU"
FT   STRAND          366..370
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          373..377
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          380..383
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          386..389
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          393..396
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            398..400
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          417..421
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          424..428
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          440..444
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            445..448
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          449..452
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          464..468
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          471..475
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          480..483
FT                   /evidence="ECO:0007829|PDB:6HWS"
FT   STRAND          487..491
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            492..495
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          496..499
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          511..515
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          518..522
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          527..530
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          534..538
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            539..542
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          543..547
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          558..562
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          565..569
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          574..577
FT                   /evidence="ECO:0007829|PDB:5F72"
FT   STRAND          580..585
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   TURN            586..589
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          590..596
FT                   /evidence="ECO:0007829|PDB:1ZGK"
FT   STRAND          605..609
FT                   /evidence="ECO:0007829|PDB:1ZGK"
SQ   SEQUENCE   624 AA;  69666 MW;  CE180F3897BB8C97 CRC64;
     MQPDPRPSGA GACCRFLPLQ SQCPEGAGDA VMYASTECKA EVTPSQHGNR TFSYTLEDHT
     KQAFGIMNEL RLSQQLCDVT LQVKYQDAPA AQFMAHKVVL ASSSPVFKAM FTNGLREQGM
     EVVSIEGIHP KVMERLIEFA YTASISMGEK CVLHVMNGAV MYQIDSVVRA CSDFLVQQLD
     PSNAIGIANF AEQIGCVELH QRAREYIYMH FGEVAKQEEF FNLSHCQLVT LISRDDLNVR
     CESEVFHACI NWVKYDCEQR RFYVQALLRA VRCHSLTPNF LQMQLQKCEI LQSDSRCKDY
     LVKIFEELTL HKPTQVMPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSDG TWLRLADLQV
     PRSGLAGCVV GGLLYAVGGR NNSPDGNTDS SALDCYNPMT NQWSPCAPMS VPRNRIGVGV
     IDGHIYAVGG SHGCIHHNSV ERYEPERDEW HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG
     TNRLNSAECY YPERNEWRMI TAMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE
     TETWTFVAPM KHRRSALGIT VHQGRIYVLG GYDGHTFLDS VECYDPDTDT WSEVTRMTSG
     RSGVGVAVTM EPCRKQIDQQ NCTC
//
